Tokyo Tape
Sign in
← Takeda Pharmaceutical

Annual report

4502.TEDINET S100TNTP
Period2023-04-01 → 2024-03-31
Filed2024-06-26
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 157
MetricValuePeriodScopeSource row
Revenue¥4.26T2023-04-01 → 2024-03-31Cons.Revenue IFRS
Revenue¥4.03T2022-04-01 → 2023-03-31Cons.Revenue IFRS
Revenue¥3.57T2021-04-01 → 2022-03-31dCons.Revenue IFRS (5-year summary)
Revenue¥3.20T2020-04-01 → 2021-03-31dCons.Revenue IFRS (5-year summary)
Revenue¥3.29T2019-04-01 → 2020-03-31dCons.Revenue IFRS (5-year summary)
Operating income¥214.1bn2023-04-01 → 2024-03-31Cons.Operating profit loss IFRS
Operating income¥490.5bn2022-04-01 → 2023-03-31Cons.Operating profit loss IFRS
Profit before tax¥52.8bn2023-04-01 → 2024-03-31Cons.Profit loss before tax IFRS
Profit before tax¥375.1bn2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS
Profit before tax¥302.6bn2021-04-01 → 2022-03-31dCons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥366.2bn2020-04-01 → 2021-03-31dCons.Profit loss before tax IFRS (5-year summary)
Profit before tax−¥60.8bn2019-04-01 → 2020-03-31dCons.Profit loss before tax IFRS (5-year summary)
Net income (owners)¥144.1bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥317.0bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥230.1bn2021-04-01 → 2022-03-31dCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥376.0bn2020-04-01 → 2021-03-31dCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥44.2bn2019-04-01 → 2020-03-31dCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income¥144.2bn2023-04-01 → 2024-03-31Cons.Profit loss IFRS
Net income¥317.0bn2022-04-01 → 2023-03-31Cons.Profit loss IFRS
Net income¥230.2bn2021-04-01 → 2022-03-31dCons.Profit loss IFRS (5-year summary)
Net income¥376.2bn2020-04-01 → 2021-03-31dCons.Profit loss IFRS (5-year summary)
Net income¥44.3bn2019-04-01 → 2020-03-31dCons.Profit loss IFRS (5-year summary)
Total assets¥15.11Tat 2024-03-31Cons.Assets IFRS
Total assets¥13.96Tat 2023-03-31Cons.Assets IFRS
Total assets¥13.18Tat 2022-03-31dCons.Total assets IFRS (5-year summary)
Total assets¥12.91Tat 2021-03-31dCons.Total assets IFRS (5-year summary)
Total assets¥12.82Tat 2020-03-31dCons.Total assets IFRS (5-year summary)
Total liabilities¥7.83Tat 2024-03-31Cons.Liabilities IFRS
Total liabilities¥7.60Tat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥7.27Tat 2024-03-31Cons.Equity IFRS
Net assets / equity¥6.35Tat 2023-03-31Cons.Equity IFRS
Net assets / equity¥5.68Tat 2022-03-31dCons.Equity IFRS
Equity (owners)¥7.27Tat 2024-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥6.35Tat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Cash & equivalents¥457.8bnat 2024-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥533.5bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥849.7bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Cash & equivalents¥966.2bnat 2021-03-31dCons.Cash and cash equivalents IFRS (5-year summary)
Cash & equivalents¥637.6bnat 2020-03-31dCons.Cash and cash equivalents IFRS (5-year summary)
Operating cash flow¥716.3bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥977.2bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥1.12T2021-04-01 → 2022-03-31dCons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥1.01T2020-04-01 → 2021-03-31dCons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥669.8bn2019-04-01 → 2020-03-31dCons.Cash flows from used in operating activities IFRS (5-year summary)
Investing cash flow−¥463.9bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥607.1bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥198.1bn2021-04-01 → 2022-03-31dCons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow¥393.5bn2020-04-01 → 2021-03-31dCons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow¥292.1bn2019-04-01 → 2020-03-31dCons.Cash flows from used in investing activities IFRS (5-year summary)
Financing cash flow−¥354.4bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥709.1bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥1.07T2021-04-01 → 2022-03-31dCons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥1.09T2020-04-01 → 2021-03-31dCons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥1.01T2019-04-01 → 2020-03-31dCons.Cash flows from used in financing activities IFRS (5-year summary)
EPS (basic)¥92.092023-04-01 → 2024-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥204.292022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥147.142021-04-01 → 2022-03-31dCons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥240.722020-04-01 → 2021-03-31dCons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥28.412019-04-01 → 2020-03-31dCons.Basic earnings loss per share IFRS (5-year summary)
EPS (diluted)¥91.162023-04-01 → 2024-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥201.942022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥145.872021-04-01 → 2022-03-31dCons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥238.962020-04-01 → 2021-03-31dCons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥28.252019-04-01 → 2020-03-31dCons.Diluted earnings loss per share IFRS (5-year summary)
Net assets per share¥4,635.56at 2024-03-31Cons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥4,087.49at 2023-03-31Cons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥3,665.61at 2022-03-31dCons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥3,308.93at 2021-03-31dCons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥3,032.22at 2020-03-31dCons.Equity to asset ratio IFRS (5-year summary)
Equity ratio48.1%at 2024-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio45.5%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio43.1%at 2022-03-31dCons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio40.1%at 2021-03-31dCons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio36.8%at 2020-03-31dCons.Ratio of owners equity to gross assets IFRS (5-year summary)
ROE2.1%2023-04-01 → 2024-03-31Cons.Rate of return on equity IFRS (5-year summary)
ROE5.3%2022-04-01 → 2023-03-31Cons.Rate of return on equity IFRS (5-year summary)
ROE4.2%2021-04-01 → 2022-03-31dCons.Rate of return on equity IFRS (5-year summary)
ROE7.6%2020-04-01 → 2021-03-31dCons.Rate of return on equity IFRS (5-year summary)
ROE0.9%2019-04-01 → 2020-03-31dCons.Rate of return on equity IFRS (5-year summary)
Employees49,281at 2024-03-31Cons.Number of employees
Employees49,095at 2023-03-31Cons.Number of employees
Employees47,347at 2022-03-31dCons.Number of employees
Employees47,099at 2021-03-31dCons.Number of employees
Employees47,495at 2020-03-31dCons.Number of employees
Revenue¥595.6bn2023-04-01 → 2024-03-31StandaloneNet sales
Revenue¥632.1bn2022-04-01 → 2023-03-31StandaloneNet sales
Revenue¥764.3bn2021-04-01 → 2022-03-31dStandaloneNet sales (5-year summary)
Revenue¥602.6bn2020-04-01 → 2021-03-31dStandaloneNet sales (5-year summary)
Revenue¥616.3bn2019-04-01 → 2020-03-31dStandaloneNet sales (5-year summary)
Operating income¥48.1bn2023-04-01 → 2024-03-31StandaloneOperating income
Operating income¥136.1bn2022-04-01 → 2023-03-31StandaloneOperating income
Ordinary income¥286.4bn2023-04-01 → 2024-03-31StandaloneOrdinary income
Ordinary income¥340.1bn2022-04-01 → 2023-03-31StandaloneOrdinary income
Ordinary income¥550.9bn2021-04-01 → 2022-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥50.0bn2020-04-01 → 2021-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥72.3bn2019-04-01 → 2020-03-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax¥391.3bn2023-04-01 → 2024-03-31StandaloneIncome before income taxes
Profit before tax¥383.0bn2022-04-01 → 2023-03-31StandaloneIncome before income taxes
Net income¥338.9bn2023-04-01 → 2024-03-31StandaloneProfit loss
Net income¥330.6bn2022-04-01 → 2023-03-31StandaloneProfit loss
Net income¥324.4bn2021-04-01 → 2022-03-31dStandaloneNet income loss (5-year summary)
Net income¥247.5bn2020-04-01 → 2021-03-31dStandaloneNet income loss (5-year summary)
Net income¥130.6bn2019-04-01 → 2020-03-31dStandaloneNet income loss (5-year summary)
Total assets¥9.76Tat 2024-03-31StandaloneAssets
Total assets¥9.41Tat 2023-03-31StandaloneAssets
Total assets¥9.64Tat 2022-03-31dStandaloneTotal assets (5-year summary)
Total assets¥10.86Tat 2021-03-31dStandaloneTotal assets (5-year summary)
Total assets¥10.29Tat 2020-03-31dStandaloneTotal assets (5-year summary)
Total liabilities¥5.67Tat 2024-03-31StandaloneLiabilities
Total liabilities¥5.20Tat 2023-03-31StandaloneLiabilities
Net assets / equity¥4.09Tat 2024-03-31StandaloneNet assets
Net assets / equity¥4.21Tat 2023-03-31StandaloneNet assets
Net assets / equity¥4.29Tat 2022-03-31dStandaloneNet assets
Net assets / equity¥4.43Tat 2021-03-31dStandaloneNet assets (5-year summary)
Net assets / equity¥4.55Tat 2020-03-31dStandaloneNet assets (5-year summary)
Cash and deposits¥130.9bnat 2024-03-31StandaloneCash and deposits
Cash and deposits¥164.9bnat 2023-03-31StandaloneCash and deposits
EPS (basic)¥216.62023-04-01 → 2024-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥213.062022-04-01 → 2023-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥207.52021-04-01 → 2022-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥158.452020-04-01 → 2021-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥83.882019-04-01 → 2020-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (diluted)¥216.562023-04-01 → 2024-03-31StandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥213.052022-04-01 → 2023-03-31StandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥207.52021-04-01 → 2022-03-31dStandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥158.442020-04-01 → 2021-03-31dStandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥83.872019-04-01 → 2020-03-31dStandaloneDiluted earnings per share (5-year summary)
Dividend per share¥1882023-04-01 → 2024-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥1802022-04-01 → 2023-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥1802021-04-01 → 2022-03-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥1802020-04-01 → 2021-03-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥1802019-04-01 → 2020-03-31dStandaloneDividend paid per share (5-year summary)
Net assets per share¥2,604.87at 2024-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥2,704.87at 2023-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥2,769.31at 2022-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥2,835.81at 2021-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥2,919.21at 2020-03-31dStandaloneNet assets per share (5-year summary)
Equity ratio41.9%at 2024-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio44.7%at 2023-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio44.5%at 2022-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio40.8%at 2021-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio44.2%at 2020-03-31dStandaloneEquity to asset ratio (5-year summary)
ROE8.2%2023-04-01 → 2024-03-31StandaloneRate of return on equity (5-year summary)
ROE7.8%2022-04-01 → 2023-03-31StandaloneRate of return on equity (5-year summary)
ROE7.4%2021-04-01 → 2022-03-31dStandaloneRate of return on equity (5-year summary)
ROE5.5%2020-04-01 → 2021-03-31dStandaloneRate of return on equity (5-year summary)
ROE2.8%2019-04-01 → 2020-03-31dStandaloneRate of return on equity (5-year summary)
Shares issued1,582,419,000at 2024-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued1,582,296,000at 2023-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued1,582,253,000at 2022-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued1,576,388,000at 2021-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued1,576,374,000at 2020-03-31dStandaloneTotal number of issued shares (5-year summary)
Employees5,474at 2024-03-31StandaloneNumber of employees
Employees5,486at 2023-03-31StandaloneNumber of employees
Employees5,149at 2022-03-31dStandaloneNumber of employees
Employees4,966at 2021-03-31dStandaloneNumber of employees
Employees5,350at 2020-03-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 2
SegmentItemPeriodValue
Pharmaceutical Businessreportable segmentemployeesat 2024-03-3149281 pure
Pharmaceutical Businessreportable segmentemployeesat 2024-03-315474 pure

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,742
ItemContextValueUnit
Dividends from surplusCurrentYearDuration_NonConsolidatedMember_ShareholdersEquityMember-288512000000JPY
Dividends from surplusCurrentYearDuration_NonConsolidatedMember-288512000000JPY
Provision of reserve for advanced depreciation of noncurrent assetsCurrentYearDuration_NonConsolidatedMember_ShareholdersEquityMember－JPY
Provision of reserve for advanced depreciation of noncurrent assetsCurrentYearDuration_NonConsolidatedMember－JPY
Reversal of reserve for advanced depreciation of noncurrent assetsCurrentYearDuration_NonConsolidatedMember_ShareholdersEquityMember－JPY
Reversal of reserve for advanced depreciation of noncurrent assetsCurrentYearDuration_NonConsolidatedMember－JPY
Profit lossCurrentYearDuration_NonConsolidatedMember_ShareholdersEquityMember338874000000JPY
Profit lossCurrentYearDuration_NonConsolidatedMember338874000000JPY
Purchase of treasury stockCurrentYearDuration_NonConsolidatedMember_TreasuryStockMember-2367000000JPY
Purchase of treasury stockCurrentYearDuration_NonConsolidatedMember_ShareholdersEquityMember-2367000000JPY
Purchase of treasury stockCurrentYearDuration_NonConsolidatedMember-2367000000JPY
Disposal of treasury stockCurrentYearDuration_NonConsolidatedMember_TreasuryStockMember51426000000JPY
Disposal of treasury stockCurrentYearDuration_NonConsolidatedMember_ShareholdersEquityMember66359000000JPY
Disposal of treasury stockCurrentYearDuration_NonConsolidatedMember66359000000JPY
Net changes of items other than shareholders equityCurrentYearDuration_NonConsolidatedMember_ShareholdersEquityMember－JPY
Net changes of items other than shareholders equityCurrentYearDuration_NonConsolidatedMember_ValuationDifferenceOnAvailableForSaleSecuritiesMember2447000000JPY
Net changes of items other than shareholders equityCurrentYearDuration_NonConsolidatedMember_DeferredGainsOrLossesOnHedgesMember-235246000000JPY
Net changes of items other than shareholders equityCurrentYearDuration_NonConsolidatedMember_SubscriptionRightsToSharesMember-77000000JPY
Net changes of items other than shareholders equityCurrentYearDuration_NonConsolidatedMember-232877000000JPY
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember_TreasuryStockMember49059000000JPY
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember_ShareholdersEquityMember114856000000JPY
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember_ValuationDifferenceOnAvailableForSaleSecuritiesMember2447000000JPY
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember_DeferredGainsOrLossesOnHedgesMember-235246000000JPY
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember_SubscriptionRightsToSharesMember-77000000JPY
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember-118021000000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_TreasuryStockMember-51229000000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_ShareholdersEquityMember4661339000000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_ValuationDifferenceOnAvailableForSaleSecuritiesMember11031000000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_DeferredGainsOrLossesOnHedgesMember-585282000000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_SubscriptionRightsToSharesMember1111000000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember4088198000000JPY
Sales commission sgaPrior1YearDuration_NonConsolidatedMember30861000000JPY
Sales commission sgaCurrentYearDuration_NonConsolidatedMember32951000000JPY
Provision for bonuses sgaPrior1YearDuration_NonConsolidatedMember7990000000JPY
Provision for bonuses sgaCurrentYearDuration_NonConsolidatedMember8976000000JPY
Depreciation sgaPrior1YearDuration_NonConsolidatedMember7806000000JPY
Depreciation sgaCurrentYearDuration_NonConsolidatedMember7792000000JPY
Business consignment expenses sgaPrior1YearDuration_NonConsolidatedMember13276000000JPY
Business consignment expenses sgaCurrentYearDuration_NonConsolidatedMember14515000000JPY
Research and development expenses sgaPrior1YearDuration_NonConsolidatedMember141050000000JPY
Research and development expenses sgaCurrentYearDuration_NonConsolidatedMember164472000000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)有価証券報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2024-06-26
Fiscal year cover pageFilingDateInstant
Original text (Japanese)第147期(自　2023年４月１日　至　2024年３月31日)
Company name cover pageFilingDateInstant
Original text (Japanese)武田薬品工業株式会社
Company name in english cover pageFilingDateInstantTakeda Pharmaceutical Company Limited
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長CEO　　クリストフ ウェバー
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)大阪府大阪市中央区道修町四丁目１番１号（上記は登記上の本店所在地で実際の業務は「最寄りの連絡場所」で行っております。）

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 21 of 21 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2024-03-31pass rounding
balance sheet identitynon_consolidated 2023-03-31pass
balance sheet identitynon_consolidated 2024-03-31pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2022-03-31pass
statement vs summary · net assetsnon_consolidated 2023-03-31pass
statement vs summary · net assetsnon_consolidated 2024-03-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2023-03-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2024-03-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2023-03-31pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2024-03-31pass
statement vs summary · revenueconsolidated 2022-04-01/2023-03-31pass
statement vs summary · revenueconsolidated 2023-04-01/2024-03-31pass
statement vs summary · revenuenon_consolidated 2022-04-01/2023-03-31pass
statement vs summary · revenuenon_consolidated 2023-04-01/2024-03-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsnon_consolidated 2023-03-31pass
statement vs summary · total assetsnon_consolidated 2024-03-31pass